Association of sarcopenia and observed physical performance with attainment of multidisciplinary team planned treatment in non-small cell lung cancer: an observational study protocol by unknown
STUDY PROTOCOL Open Access
Association of sarcopenia and observed
physical performance with attainment of
multidisciplinary team planned treatment
in non-small cell lung cancer: an
observational study protocol
Jemima T. Collins1,2*, Simon Noble2, John Chester3, Helen E. Davies4, William D. Evans5, Jason Lester3, Diane Parry4,
Rebecca J. Pettit5 and Anthony Byrne1
Abstract
Background: Non-small cell lung cancer (NSCLC) frequently presents in advanced stages. A significant proportion
of those with reportedly good ECOG performance status (PS) fail to receive planned multidisciplinary team (MDT)
treatment, often for functional reasons, but an objective decline in physical performance is not well described.
Sarcopenia, or loss of muscle mass, is an integral part of cancer cachexia. However, changes in both muscle mass
and physical performance may predate clinically overt cachexia, and may be present even with normal body mass
index. Physical fitness for treatment is currently subjectively assessed by means of the PS score, which may be
inadequate in predicting tolerance to treatment. This study aims to evaluate whether measuring physical
performance and muscle mass at baseline in NSCLC patients, in addition to PS score, is able to predict
commencement and successful completion of MDT-planned treatment.
Methods/design: This is a prospective, single-centre exploratory study of NSCLC patients attending a Rapid Access
Lung Cancer clinic. Baseline data collected are (methods in brackets): physical performance (Short Physical Performance
Battery), muscle mass (bioelectrical impedance ± dual energy x-ray absorptiometry), patient and physician-assessed PS
(ECOG and Karnofsky), nutritional status and presence of cachexia. Longitudinal data consists of receipt and completion
of MDT treatment plan. The primary outcome measure is commencement of MDT-planned treatment, and important
secondary outcomes include successful completion of treatment, length of stay in surgical patients, and risk of
chemotherapy- and radiotherapy-related side effects.
Discussion: A more comprehensive assessment of phenotype, particularly with regards to physical performance and
muscle mass, will provide additional discriminatory information of patients’ fitness for treatment. If positive, this study
has the potential to identify targets for early intervention in those who are at risk of deterioration. This will
subsequently enable optimisation of performance of patients with NSCLC, in anticipation of systemic treatment.
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Background
Lung cancer is a common disease, with a global incidence
of 1.61 million in 2008 [1, 2]. Non-small cell lung cancer
(NSCLC) is the most common cell type, with the majority
of patients presenting with advanced disease. Despite ad-
vances in anticancer treatments, the mortality risk of lung
cancer remains high worldwide, with an annual mortality
to incidence ratio of 88 % [3]. In the United Kingdom, an-
nual mortality from NSCLC is similarly poor, with an
overall 5-year survival rate of 8.6 % [4].
Despite this, survival rates in NSCLC are consistently su-
perior in patients who receive specific anticancer treat-
ment, compared to those who do not [5–7]. Potentially
curative treatment strategies using surgery, radical radio-
therapy or multimodality treatment is feasible in a minority
of patients (12–19 %), whilst systemic anti-cancer therapy
is recommended for those with incurable disease [8–10].
Multidisciplinary team (MDT) assessment of fitness for op-
timal treatment – be it surgery, radiotherapy or chemo-
therapy, singly or in combination – is crucial, as all these
modalities are poorly tolerated by patients with low base-
line physical function [11, 12]. Currently assessment of fit-
ness for treatment is based on initial clinical examination,
consideration of co-morbidities and clinician assessment of
functioning, most often reported as Eastern Cooperative
Oncology Group (ECOG) or Karnofsky performance status
(PS) [13, 14]. Evidence suggests that PS assessment at base-
line is predictive of overall survival [15, 16]. However, there
is less evidence of sensitivity to change over time or of reli-
able correlations with tolerance of treatment. Furthermore,
PS assessment is subjective, with reports of inter-observer
variability [17, 18], and there may only be a modest correl-
ation between PS and observed physical performance [19].
Most tellingly, recent evidence also suggests that up to
33 % of NSCLC patients for whom active treatment is rec-
ommended by the MDT do not go on to receive it, mainly
due to functional reasons [20, 21].
Physical function is largely dependent on maintenance
of muscle mass and neuromuscular function. Although
weight loss has long been recognised as an adverse fea-
ture of cancer cachexia, it is the depletion of skeletal
muscle mass – sarcopenia – with or without loss of fat
mass, which is now an integral part of the diagnosis of
cancer cachexia [22]. Its presence is associated with an
increased risk of post-operative morbidity, longer hos-
pital stays, as well as poorer survival [23–26]. Depletion
of muscle mass may also give rise to chemotherapy tox-
icities and a poorer response to chemotherapy. In a
study of NSCLC patients, variation in muscle mass per
unit of body surface area accounted for up to three
times the variation of chemotherapy volume of distribu-
tion, thus contributing to under- or over-dosing [26].
Clinically, this may manifest as increased risk of dose-
limiting toxic side effects in sarcopenic patients, as has
been reported in breast, hepatocellular and renal cancer
[27–29].
Whilst these studies attest to the importance of muscle
mass, less attention has been paid to muscle function
(strength and physical performance) as part of the evalu-
ation of sarcopenia in cancer. Muscle mass is linked to
muscle function in a non-linear fashion in the elderly,
and consequently muscle mass alone cannot fully ac-
count for poor outcomes associated with sarcopenia
[30–32]. As a geriatric syndrome, therefore, the import-
ance of overall neuromuscular function is recognised,
with the recommendation that sarcopenia be defined as
a combination of loss of physical performance as well as
muscle mass [33]. However, the value of assessing phys-
ical performance in lung cancer, particularly with regards
to tolerance of treatment, is not known.
In light of this gap in knowledge, calls have been made
for objective assessments of physical performance which
have prognostic value, to evaluate tolerance of systemic
treatment [34, 35]. The gold standard method of assessing
physical fitness (cardiopulmonary exercise testing) is
laboratory-based and not always feasible for use in pa-
tients with malignancy [36]. In addition, it is not widely
available and takes over 2 hours to perform and report
one case. Other more commonly used tests such as the 6-
minute walk test (6MWT) can be challenging to use in
clinical practice and is often reserved as research tools
[34, 37]. The term ‘physical performance’ in this context
implies the ability to undertake physical tasks which are
dependent on different physiological domains [38]. Utilis-
ing a measurement tool which assesses overall function is
therefore more appropriate, and is in keeping with guide-
lines for the elderly. The Short Physical Performance Bat-
tery (SPPB) is one such test, measuring balance, gait
speed, lower limb strength and endurance – all crucial in
performing activities of daily living. It is a valid, reliable
and feasible measure of physical performance in older
people [39, 40]. It is quick to perform, easily replicable, re-
quires little additional equipment, and with basic training
can be performed by most healthcare personnel.
In the assessment of sarcopenia, current gold standard
techniques of measuring muscle mass include computed
tomography (CT) and dual energy x-ray absorptiometry
(DXA) [41]. However, these techniques involve radiation
and either additional investigations (DXA) or extension
of current CT staging scans to the L3 level with add-
itional software and expertise for interpretation. By con-
trast, bioelectrical impedance (BIA) measures muscle
mass quickly and easily in clinic, with no radiation ex-
posure. It operates through the application of a small,
painless electrical current through the body, which en-
ables calculation of the proportions of fat and muscle
mass [42]. It is one of the key methods for assessment of
muscularity cited in the new definition of cancer
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cachexia [22], and is a practical tool for measurement of
body composition in cancer patients [43–45].
Whilst current retrospective evidence suggests that
muscle mass depletion is associated with increased
treatment-related adverse events, it is unclear to what
extent measures of muscle mass as well as function at
baseline can predict ability to receive and tolerate treat-
ment, and whether they might outperform current
methods of MDT assessment. Understanding this may
enable more efficient delivery of treatment to this vul-
nerable patient group, enabling rationalisation of health-
care provision. In addition, it may identify targets for
intervention allowing optimisation of patient perform-
ance in anticipation of systemic treatment.
Study aims and design
Primary aim
To explore whether measures of skeletal muscle mass
and physical performance, at first presentation, can pre-
dict commencement of MDT-planned treatment in pa-
tients with NSCLC.
Secondary aims
In patients with NSCLC
1. To evaluate the value of baseline measurements of
muscle mass and physical performance as predictors
of successful completion of MDT-planned
treatment.
2. To explore the prevalence of low muscle mass
(sarcopenia) and its relationship to physical
performance and degree of chemotherapy-related
side effects.
3. To explore the relationship between PS and muscle
mass, physical performance and nutrition status.
4. To evaluate the utility of BIA as a practical clinical
tool for estimating muscle mass, using DXA as the
gold standard comparator in a sub-group of patients.
5. To assess the feasibility of assessing physical
performance using SPPB in the rapid access lung
clinic setting.
Patient recruitment
A target of 100 participants with new suspected NSCLC
are being recruited from the Rapid Access Chest Clinic
(RACC) in a single-centre, University Hospital setting. Ap-
proximately 410 new patients attend this clinic each year.
Of patients attending a RACC, 36–50 % have a subsequent
diagnosis of primary lung malignancy, and of this 81 % have
NSCLC [46, 47]. These figures suggest that our expected
recruitment target of 100 over 18 months is achievable.
Introduction to the study will be at the discretion of the
chest physicians in the clinic, who will decide when it is
appropriate to offer an invitation based on likelihood of
NSCLC diagnosis and level of emotional distress.
Ethical considerations
It is important to acknowledge some of the ethical chal-
lenges this study brings. Patients are recruited before a
definitive diagnosis of NSCLC has been made. This em-
phasises the importance of appropriate participant selec-
tion by the chest physicians acting as gatekeepers, who
only offer participation in the study based on a high clin-
ical likelihood of NSCLC, patients’ understanding of this
and their level of emotional distress. In addition, recruit-
ment on the same day as first presentation can present a
challenge in terms of gaining informed consent and tim-
ing around other investigations. However, this will en-
able capture of feasibility and acceptability data, which
may be of use to the MDT for planning of future ser-
vices. Having acknowledged these challenges and ensur-
ing that the Patient Information Leaflet and Consent
forms reflect this, the South East Wales Research Ethics
Committee granted a favourable opinion in November
2013 (REC reference 13/WA/0254).
Sample size
To the best of our knowledge, there are no current stud-
ies evaluating the relationship of both muscle mass and
physical performance to treatment outcomes for lung
cancer patients; therefore power calculations to estimate
optimal sample size are not possible.
Inclusion criteria
 Patients with non-small cell lung cancer (NSCLC)
based on clinical and radiological suspicion.
 Clinician-scored ECOG PS 0–2 at presentation.
 Age 18 years or more.
Exclusion criteria
 Presence of implantable cardioverter defibrillator or
pacemaker.
 Patients who have had strenuous activity or
excessive alcohol within 24 h prior to the study, or
patients with significant peripheral oedema, all of
which may alter the accuracy of BIA measurements.
 Patients with neurological or physical impediment
which would preclude participation in the study.
 Inability to give informed consent due to insufficient
ability to understand and communicate in English.
Study assessments
Baseline information
The following information is collected from participants’
medical notes: weight and height, degree of any recent
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weight loss, co-morbidities including severity of chronic
obstructive pulmonary disease (COPD) if present, use of
non-steroidal anti-inflammatory medicines (NSAIDs) or
steroids, and routine blood test results (haemoglobin,
albumin, and C-reactive protein).
Muscle mass
Predicted muscle mass (MM) is measured using BIA
(Tanita BC-418). Participants are asked to place their
hands and feet on to the machine which resembles a
weighing scale. A printout of the participant’s body com-
position is generated, accounting for age and gender.
This assessment takes roughly 1 min and is repeated in
order to calculate precision. To assess the accuracy of
BIA-derived muscle mass, this is compared to whole
body DXA (Hologic Discovery A) measurements of lean
tissue mass in a subgroup of patients (n = 20) (this is
performed within 3 days of BIA). The DXA scan in-
volves lying flat in the supine position for 5 min, while
the machine’s scanning arm runs over the patient’s body.
The estimated radiation of this scan is 4.2 microsieverts,
which is comparable to the risk associated with one day’s
worth of natural background radiation [48].
Physical performance
In order to assess objectively physical performance, the
Short Physical Performance Battery (SPPB) is utilised
[49]. It consists of balance, gait speed and chair stand
tests which take between 7 and 10 min to perform. The
balance tests assess the participants’ ability to hold these
positions for 10 s: (i) both feet together (side-by-side),
(ii) heel of one foot touching the big toe of the other
(semi-tandem stand) and (iii) heel of one foot in front of
and touching the toes of the other (tandem stand). The
gait speed test consists of two timed walks of 4 metres
each, at the participant’s usual walking pace. The chair
stands test consists of five timed stands from a sitting
position without the use of arms. As the SPPB is the
most time-consuming portion of the study assessments,
we will give participants the option of being tested at
home, provided this is done within 3 days. In this in-
stance, the research team will arrange to visit them at a
place of their choice e.g. their home.
Performance status
Both physician- and patient-assessed PS scores (ECOG and
Karnofsky scales) are obtained and noted. For the purposes
of patient-assessed PS, lay wording was taken directly from
the Cancer Research UK website, with permission [50]. We
have omitted the descriptions of 5 on the ECOG scale and
0 on the Karnofsky, to minimise distress.
Nutrition status
The Malnutrition Universal Screening Tool (MUST)
[51] is a simple and quick method of screening for mal-
nutrition in at-risk patients, based on body mass index,
unplanned weight loss and recent nutritional intake. It
has been validated in patients with cancer [52].
Outcome measures
Primary outcome measure
The primary outcome measure is defined as a binary
outcome – yes or no. This is determined as receipt of
the MDT-planned surgical procedure or commencement
of MDT-planned radiotherapy or chemotherapy course.
Secondary outcome measure
Successful completion of MDT-planned treatment is
noted. For chemotherapy this will be defined as receipt
of the pre-planned number of treatments at pre-planned
dose intensity; for surgery, receipt of the pre-planned
intervention and for radiotherapy, completion of the
pre-planned number of fractions at the pre-defined dose
intensity.
Progress through chemotherapy
For the purposes of this study, we will note the type and
grade of toxicity by Common Terminology Criteria for
Adverse Events (CTCAE) criteria, if any, its frequency
and requirement for dose reduction, and the number of
cycles of chemotherapy completed.
Progress through other treatment courses
We will note the completion of the surgical intervention,
length of stay and any post-operative complications. For
participants undergoing RT, we will document any
radiotherapy toxicities and the number of fractions
completed.
Data analysis
Correlations between independent variables – muscle
mass, SPPB scores, age, gender, performance status and
treatment receipt and successful completion will be ana-
lysed using logistic regression. Any associations between
the presence of sarcopenia and the outcome measures of
interest will be analysed. For secondary outcomes we
will assess the strength of correlations by calculating
correlation coefficients and their 95 % confidence inter-
vals. We aim to document the strength of agreement be-
tween DXA- and BIA-derived muscle mass values with
intraclass correlation coefficient (ICC), where an ICC of
more than 0.75 is generally considered excellent.
Discussion
The majority of patients with lung cancer present in ad-
vanced stages, many incurable with a median survival of
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9–12 months [53]. For treatment to have its optimum ef-
fect, it needs to be initiated in a timely manner, with ap-
propriate patient selection, taking into account levels of
physical fitness for treatment. In its latest guidance on
lung cancer, the National Institute for Health and Clinical
Excellence (NICE) assert that factors predicting success in
treatment in patients with borderline fitness levels is as
yet unclear. It therefore recommends robust, consistent
and meaningful studies into assessments of fitness param-
eters, with appropriately designed trials [54].
The patient’s journey between first presentation with
suspected lung cancer and review by the treating oncolo-
gist or surgeon is not well-described; however there is evi-
dence that a significant proportion of patients are unable
to receive all of their MDT-planned treatment, for func-
tional reasons [20, 21]. Objective, formalised assessment
of physical performance alongside assessment of muscle
mass at baseline may provide additional discriminatory in-
formation, as an adjunct to PS, which would better inform
MDT decisions. There are many candidate tools for asses-
sing physical performance and muscle mass [37, 41].
However, as well as being reliable and having predictive
validity, the best methods should also be easily performed
in clinical settings, alongside other measurements of body
mass index, body surface area and performance status.
As interest intensifies in the role of wider supportive
interventions for cancer patients, understanding baseline
levels of muscle mass and physical function is of grow-
ing importance in defining individualised supportive care
plans. There is good evidence that exercise programmes
have varied, beneficial outcomes for cancer patients in-
cluding improved levels of cardio-respiratory fitness, ob-
jective performance, self-reported functioning and
reduced cancer-related fatigue in systemic treatment
[55–57]. Even in NSCLC patients with advanced disease,
there is emerging evidence that exercise may have a
favourable role [37, 58]. However, it is currently unclear
at what time point this should be initiated to obtain
greatest benefit, the type and intensity of the interven-
tion and whether early initiation can improve tolerance
of treatment in this patient group. A multi-dimensional
assessment of physical functioning at baseline would
allow early identification of patients at greatest risk of
functional decline and thereby stratification for enrol-
ment in exercise programmes or other interventions, in
preparation for systemic anticancer treatment.
In summary, measurement of patient performance and
muscle mass, using validated and easily replicated tools,
may add important objective detail of patients’ physical
fitness to the currently utilised PS score and aid MDT
decision making. These assessments would enable more
accurate prediction of successful attainment of thera-
peutic goals highlighting patients at potential risk from
planned treatments and thereby allowing intervention to
be targeted at individual functional domains. This could
have potential implications for MDT co-ordination and
clinical service provision yet ensure efficient and prudent
patient care.
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